Targets that offer more specific immune modulation (and could therefore improve the risk/benefit profile) or more convenient routes of administration (through oral or extended activity formulations) are of particularly high interest to our team in the years ahead.
Autoimmune and inflammatory diseases are key areas that we believe have plenty of unmet need and growth potential over the next decade. The unprecedented availability of private capital has enabled many private companies to be built around treatments for many patient indications in these areas. Targets that offer more specific immune modulation (and could therefore improve the risk/benefit profile) or more convenient routes of administration (through oral or extended activity formulations) are of particularly high interest to our team in the years ahead.